AWARD-6 is a randomized, open, parallel-grouped, multicenter, phase 3, non-inferiority study comparing the safety and efficacy of weekly DUL and daily LIR in patients with uncontrolled T2DM treated with metformin
For many patients, the answer will be yes the medication is bioequivalent, the injection device is comparable, and the cost savings are real
Standalone CJC-1295 The CJC-1295 ipamorelin blend is ideal for researchers studying dual-pathway GH axis activation and synergistic GH release mechanisms
Both are FDA-approved weekly injectable weight loss medications
These changes build on Caremarks industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost
Diabetes Drugs in the Fight Against Alzheimers Disease